Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

• ClinicalTrials.gov Identifier: NCT02500979
• Recruitment Status: Completed
• First Posted: July 17, 2015
• Results First Posted: November 2, 2018
• Last Update Posted: November 2, 2018
• Sponsor: AstraZeneca
• Collaborator: Juvenile Diabetes Research Foundation
• Information provided by (Responsible Party): AstraZeneca

Study Description

Brief Summary:

This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.

Condition or disease	Intervention/treatment	Phase
Type 1 Diabetes Mellitus	Drug: Pramlintide acetate; Drug: Placebo; Drug: Lispro insulin U-100; Drug: Regular insulin U-100	Phase 1

Detailed Description:

Potentially eligible subjects with Type 1 diabetes mellitus who are treated with with a basal-bolus insulin regimen through multiple daily injections or insulin pump at a total daily insulin dose ≤60 U, will be eligible. Visit 1 is approximately 3-6 weeks prior to randomization. Given some variability in HbA1c and C-peptide assays, re-testing for HbA1c and C-peptide can be performed within 18 days from the initial visit. Visit 2 is approximately 2-5 weeks prior to randomization. Subjects are on lispro insulin throughout study except during Visit 4 and Visit 5, the domicile 24 hr treatment period, when they are switched to regular insulin U-100.

Screen failed patients may be re-screened for inclusion in the study, as long as re-screening takes place at least 3 months after the original screening visit. If a subject is re-screened, he/she must continue to meet all inclusion/exclusion criteria. All study procedures of initial Visit 1 must be repeated at the re-screening visit.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 34 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Single (Participant)
• Primary Purpose: Treatment
• Official Title: A Randomized, Single-Blind, Two-Way Crossover, Placebo-Controlled Phase I Study to Compare the 24-hour Glucose Profile and Safety of Pramlintide and Insulin, Co-Administered in a Fixed-Dose Ratio, Versus Placebo and Insulin in Patients With Type 1 Diabetes Mellitus With Inadequate Glycemic Control
• Actual Study Start Date: August 17, 2015
• Actual Primary Completion Date: August 5, 2016
• Actual Study Completion Date: August 5, 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Pramlintide acetate & regular insulin; Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL	Drug: Pramlintide acetate; Pramlintide acetate administered by a separate pump; Other Name: Pramlintide: SYMLIN; Drug: Lispro insulin U-100; Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5); Other Name: Humalog insulin lispro U-100; Drug: Regular insulin U-100; Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump; Other Name: Humulin R; U-100
Placebo Comparator: Placebo and regular insulin; Placebo is similar sterile solution without pramlintide.	Drug: Placebo; Placebo administered by separate pump; Drug: Lispro insulin U-100; Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5); Other Name: Humalog insulin lispro U-100; Drug: Regular insulin U-100; Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump; Other Name: Humulin R; U-100

Outcome Measures

Primary Outcome Measures :

1. Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM) [ Time Frame: 24 h ]
   24-hour MWG mg/dL, defined as total area under the 24-hour tissue glucose curve obtained with CGM, divided by actual time span in the 24-hour period.

Secondary Outcome Measures :

1. Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Lunch [ Time Frame: 3 hours ]
   Absolute postprandial plasma glucose AUC was measured for the first 3 hours (AUC0-3h) following lunch based on sample availability. (Sample times: 20 hours [lunch], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
2. Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Dinner [ Time Frame: 2 hours ]
   Absolute postprandial plasma glucose AUC (AUC0-2h) was measured for the first 2 hours following dinner based on sample availability. (Sample times: 2 hours [dinner], 2 hours 45 min, 3 hours, 4 hours).
3. Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Breakfast [ Time Frame: 2 hours ]
   Absolute postprandial plasma glucose AUC (AUC0-2h) was measured for the first 2 hours following breakfast based on sample availability. (Sample times: 16 hours [breakfast], 16 hours 45 min, 17 hours, 18 hours).
4. Efficacy of Pramlintide by Measurement of Incremental 24-hour Tissue Glucose Area Under the Plasma Concentration-time Curve (AUC) Obtained With Continuous Glucose Monitoring (CGM) [ Time Frame: 24 h ]
   Incremental (i.e., baseline-corrected) area under the 24-hour tissue glucose concentration curve (AUC0-24h) measured by continuous glucose monitoring (CGM) with a pre-test, non-fasting tissue glucose value as baseline. (Sample times: 0, 30 min, 2 hours [dinner], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours [breakfast], 16 hours 45 min, 17 hours, 18 hours, 20 hours [lunch], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
5. Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) [ Time Frame: 24 h ]
   Absolute mean area under the 24-hour plasma glucose concentration curve, measured as total area under the curve (0 to 24 hours). (Sample times: 0, 30 min, 2 hours [dinner], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours [breakfast], 16 hours 45 min, 17 hours, 18 hours, 20 hours [lunch], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
6. Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) [ Time Frame: 24 hours ]
   Incremental (i.e., baseline-corrected) mean area under the 24-hour plasma glucose concentration curve, measured as total area under the curve (0 to 24 hours). (Sample times: 0, 30 min, 2 hours [dinner], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours [breakfast], 16 hours 45 min, 17 hours, 18 hours, 20 hours [lunch], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
7. Efficacy of Pramlintide Measured by Percent Time Spent in the Range of >70 mg/dL to <180 mg/dL Tissue Glucose Obtained With Continuous Glucose Monitoring (CGM) [ Time Frame: 24 h ]
   Percent time spent in the normoglycemic range of tissue glucose concentrations between >70 mg/dL and <180 mg/dL, measured by CGM. (Sample times: 0, 30 min, 2 hours [dinner], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours [breakfast], 16 hours 45 min, 17 hours, 18 hours, 20 hours [lunch], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
8. Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC) [ Time Frame: 24 h ]
   Absolute mean area under the 24-hour plasma glucagon concentration curve, measured as total area under the curve (total AUC0-24). (Sample times: 0, 30 min, 2 hours [dinner], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours [breakfast], 16 hours 45 min, 17 hours, 18 hours, 20 hours [lunch], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
9. Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC) [ Time Frame: 24 h ]
   Incremental (i.e., baseline-corrected) mean area under the 24-hour plasma glucagon concentration curve with a pre-test, non-fasting plasma glucagon value as baseline. (Sample times: 0, 30 min, 2 hours [dinner], 2 hours 45 min, 3 hours, 4 hours, 9 hours, 12 hours, 14 hours, 16 hours [breakfast], 16 hours 45 min, 17 hours, 18 hours, 20 hours [lunch], 20 hours 45 min, 21 hours, 23 hours, 24 hours).
10. Fasting Plasma Glucose Concentration [ Time Frame: 12 hours after dinner meal ]
    Fasting plasma glucose concentration at 0600 hours (6:00 AM)
11. Pharmacokinetics of Insulin as Demonstrated by 24-hour Plasma Insulin Area Under the Plasma Concentration-time Curve (AUC) [ Time Frame: 24 hours ]
    Mean areas under the plasma insulin concentration curves for the 24-hour periods of pramlintide and placebo administration (Sample times: -15 min, 0, 30 min, 1 hour 30 min, 2 hours [dinner], 2 hours 15 min, 2 hours 30 min, 2 hours 45 min, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, 15 hours, 16 hours [breakfast], 16 hours 15 min, 16 hours 30 min, 16 hours 45 min, 17 hours, 18 hours, 19 hours, 20 hours [lunch], 24 hours).
12. Pharmacokinetics of Insulin as Demonstrated by 24-hour Average Plasma Insulin Concentration. [ Time Frame: 24 hours ]
    Mean values of the average plasma insulin concentrations over the 24-hour periods of pramlintide and placebo administration. (Sample times: -15 min, 0, 30 min, 1 hour 30 min, 2 hours [dinner], 2 hours 15 min, 2 hours 30 min, 2 hours 45 min, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, 15 hours, 16 hours [breakfast], 16 hours 15 min, 16 hours 30 min, 16 hours 45 min, 17 hours, 18 hours, 19 hours, 20 hours [lunch], 24 hours).
13. Pharmacokinetics of Insulin as Demonstrated by Maximum Plasma Insulin Concentration [ Time Frame: 24 hours ]
    Mean maximum plasma insulin concentrations over the 24-hour periods of pramlintide and placebo administration. (Sample times: -15 min, 0, 30 min, 1 hour 30 min, 2 hours [dinner], 2 hours 15 min, 2 hours 30 min, 2 hours 45 min, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, 15 hours, 16 hours [breakfast], 16 hours 15 min, 16 hours 30 min, 16 hours 45 min, 17 hours, 18 hours, 19 hours, 20 hours [lunch], 24 hours).
14. Pharmacokinetics of Insulin as Demonstrated by the Time to the Maximum Plasma Insulin Concentration [ Time Frame: 24 hours ]
    Mean time to maximum plasma insulin concentrations over the 24-hour periods of pramlintide and placebo administration. (Sample times: -15 min, 0, 30 min, 1 hour 30 min, 2 hours [dinner], 2 hours 15 min, 2 hours 30 min, 2 hours 45 min, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, 15 hours, 16 hours [breakfast], 16 hours 15 min, 16 hours 30 min, 16 hours 45 min, 17 hours, 18 hours, 19 hours, 20 hours [lunch], 24 hours).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Provision of informed consent prior to any study-specific procedures
• Female and/or male aged between 18 and 70 years
• Must have a prior diagnosis of T1DM
• Body mass index (BMI) <30 kg/m2
• Subjects are not on current treatment with pramlintide (Symlin) and have not received pramlintide during the 6-month period prior to enrollment
• Subjects should be willing to consume all of the components of the standardized meals administered during the study
• Negative serum pregnancy test for female subjects of childbearing potential
• Female subjects of childbearing potential must be 1 year postmenopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study
• Male subjects must be surgically sterile or using an acceptable method of contraception for the duration of the study

Exclusion Criteria:

• Recurrent severe hypoglycemia requiring assistance within 6 months before screening
• A history of hypoglycemia unawareness
• A confirmed diagnosis of gastroparesis
• Has been treated, is currently being treated, or is expected to require or undergo treatment with the following medications:
• Any oral antihyperglycemic agent or any other injectable antihyperglycemic agent that is not insulin
• Drugs that directly affect GI motility (eg, anticholinergic agents such as atropine)
• Drugs that slow the intestinal absorption of nutrients (eg, α-glucosidase inhibitors
• A history of gastric surgery (such as gastric banding, Roux- and Y bypass)
• Is expected to require or undergo treatment with acetaminophen after enrollment and at any point during the study
• Has experienced diabetic ketoacidosis within the last 24 weeks
• History of hospitalization within the last 6 months for glycemic control (for both hyperglycemia or hypoglycemia)
• Subject has any significant disease or disorder, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate in the study
• Any clinically relevant abnormal findings, which, in the opinion of the investigator, may put the subject at risk because of his/her participation in the study.
• Pregnancy confirmed by a positive pregnancy test, or otherwise verified.
• Breast feeding
• Positive hepatitis C virus antibody (HCV Ab), hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibody (anti-Hbc), or human immunodeficiency virus 1/2 antibody (HIV-1/2 Ab) at Screening
• History of, or current alcohol or drug abuse
• Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate blood during the study
• Has had a major surgery or a blood transfusion within 2 months before Visit 1 (screening)
• Participation in any clinical study with an investigational drug or new formulation of a marketed drug during the last 1 month prior to Visit 1

Contacts and Locations

Locations

United States, California

Research Site

Chula Vista, California, United States, 91911

United States, Oregon

Research Site

Portland, Oregon, United States, 97239

United States, Tennessee

Research Site

Chattanooga, Tennessee, United States, 37411

Sponsors and Collaborators

AstraZeneca

Juvenile Diabetes Research Foundation

Investigators

• Study Director: Peter Ohman, MD; Medical Director AstraZeneca

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Riddle MC, Nahra R, Han J, Castle J, Hanavan K, Hompesch M, Huffman D, Strange P, Öhman P. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study. Diabetes Care. 2018 Nov;41(11):2346-2352. doi: 10.2337/dc18-1091. Epub 2018 Sep 13.

• Responsible Party: AstraZeneca
• ClinicalTrials.gov Identifier: NCT02500979
• Other Study ID Numbers: D5570C00002
• First Posted: July 17, 2015
• Results First Posted: November 2, 2018
• Last Update Posted: November 2, 2018
• Last Verified: March 2018

Keywords provided by AstraZeneca:

Type 1 Diabetes Mellitus; Pramlintide

Additional relevant MeSH terms:

Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases; Insulin; Insulin, Globin Zinc; Insulin Lispro; Pramlintide; Islet Amyloid Polypeptide; Hypoglycemic Agents; Physiological Effects of Drugs; Appetite Depressants; Anti-Obesity Agents; Amylin Receptor Agonists; Molecular Mechanisms of Pharmacological Action